Jpmorgan Chase & CO Mirum Pharmaceuticals, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding MIRM
# of Institutions
172Shares Held
54.2MCall Options Held
96.1KPut Options Held
54.8K-
Frazier Life Sciences Management, L.P. Menlo Park, CA6.5MShares$263 Million13.09% of portfolio
-
Janus Henderson Group PLC London, X04.99MShares$202 Million0.09% of portfolio
-
Bvf Inc San Francisco, CA4.37MShares$177 Million4.57% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.61MShares$146 Million2.18% of portfolio
-
Black Rock Inc. New York, NY3.24MShares$131 Million0.0% of portfolio
About Mirum Pharmaceuticals, Inc.
- Ticker MIRM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,751,700
- Market Cap $1.49B
- Description
- Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the trea...